CRBU
HealthcareCaribou Biosciences, Inc.
$1.61
+$0.02 (+1.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Caribou Biosciences, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $150.48M and 147 employees. The company generates revenue primarily through its operations in the biotechnology industry. The company's financial health is marked by significant losses, with net income totaling -$157,127,008 over the trailing twelve months. Its profitability metrics are negative, including a gross margin of 0.0%, operating margin of -1337.6%, and profit margin of 0.0%. Return on Equity (ROE) and Return on Assets (ROA) are also negative at -74.3% and -32.4%, respectively. The company has a debt-to-equity ratio of 17.95 and a current ratio of 5.54, indicating manageable liquidity despite significant losses. The company's valuation metrics include a forward P/E ratio of -0.81 and an EV/EBITDA ratio of -0.20, suggesting a high level of volatility in the stock price. The revenue growth rate is 8.6% year-over-year, but the earnings growth rate is not available. Dividend information is also not applicable, with a dividend yield of N/A and a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Visit website →Key Statistics
- Market Cap
- $150.48M
- P/E Ratio
- N/A
- 52-Week High
- $3.54
- 52-Week Low
- $0.66
- Avg Volume
- 2.32M
- Beta
- 2.62
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 147